Welcome to our dedicated page for Fate Therapeutic SEC filings (Ticker: FATE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Fate Therapeutics, Inc. (FATE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Fate Therapeutics is a clinical-stage biopharmaceutical company whose common stock trades on the Nasdaq Global Market, and its Exchange Act reports offer detailed information on financial condition, clinical programs, and corporate actions related to its iPSC-derived cellular immunotherapy pipeline.
Among the key documents available are current reports on Form 8-K, where Fate Therapeutics reports material events such as quarterly financial results, corporate restructuring decisions, clinical data updates, and executive appointments. For example, recent 8-K filings describe financial results for specific quarters, a restructuring that includes a workforce reduction to streamline operations and extend cash runway, and detailed summaries of new and updated FT819 clinical data presented at scientific meetings. Other 8-K filings outline changes in board composition and the appointment of a Chief Financial Officer, including associated compensation terms and inducement equity awards.
Investors can also use SEC filings to confirm the company’s trading status, as Fate Therapeutics’ common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the Nasdaq Global Market under the symbol FATE. Filings disclose the company’s principal executive office location by city and state, the par value of its common stock, and the use of inducement equity plans under Nasdaq Listing Rule 5635(c)(4).
On Stock Titan, each new Fate Therapeutics filing is captured from EDGAR and paired with AI-powered summaries that highlight the most important points, such as clinical milestones, restructuring charges, or changes in leadership. Users can quickly scan Form 8-K items, then drill down into the full text for deeper analysis, helping them understand how regulatory disclosures relate to the company’s iPSC-derived CAR T-cell and NK-cell development strategy.
Fate Therapeutics reported new equity awards to Chief Legal and Compliance Officer Cindy Tahl. On January 15, 2026, she was granted 100,000 shares of common stock at an acquisition price of $0.00, reported as an award of restricted stock units. These RSUs vest in four equal installments on January 8, 2027, 2028, 2029 and 2030, with each RSU converting into one share of common stock upon settlement. Following this grant, she beneficially owns 487,081 common shares directly.
She was also granted a stock option for 400,000 shares of common stock with an exercise price of $1.05 per share. This option vests in 36 equal monthly installments after January 1, 2026, becoming fully vested and exercisable on January 1, 2029, contingent on continued service with the company.
Fate Therapeutics Chief Financial Officer Adawi Kamal reported new equity awards, including restricted stock units and stock options. On January 15, 2026, Kamal received 25,000 restricted stock units that vest in four equal installments on January 8 of each year from 2027 through 2030, subject to continued service. Each unit represents the right to receive one share of common stock upon settlement.
Kamal was also granted stock options for 75,000 shares of common stock at an exercise price of $1.05 per share. These options vest in 36 equal monthly installments following January 1, 2026, becoming fully vested and exercisable on January 1, 2029, if service continues. After these grants, Kamal beneficially owned 100,000 shares of common stock directly and held 75,000 stock options.
Fate Therapeutics reported that its President and CEO, Bahram Valamehr, received new equity awards. On January 15, 2026, he was granted 335,000 shares of common stock at a price of $0.00, representing restricted stock units that vest in four equal parts on January 8 of 2027, 2028, 2029 and 2030, contingent on continued service. On the same date, he was also granted a stock option for 1,300,000 shares of common stock at an exercise price of $1.05 per share, vesting in 36 equal monthly installments after January 1, 2026, and becoming fully vested on January 1, 2029, subject to continued service. Following the stock award, he beneficially owned 664,708 shares of common stock directly, and held 1,300,000 stock options directly.
Fate Therapeutics Chief Legal and Compliance Officer Cindy Tahl reported an automatic sale of company stock tied to restricted stock unit (RSU) vesting. On January 9, 2026, she sold 10,589 shares of common stock at a weighted average price of $1.0648 per share, with individual sale prices ranging from $1.05 to $1.09. The filing explains these were the required number of shares sold to cover tax withholding obligations arising from the vesting of 17,500 RSU-based shares granted on January 15, 2025 and 8,326 RSU-based shares granted on January 25, 2022. The transactions were executed under a pre-arranged “sell-to-cover” election and were not made at her discretion. After the sales, Tahl beneficially owned 387,081 shares of Fate Therapeutics common stock directly.
Fate Therapeutics President and CEO Bahram Valamehr reported the sale of 5,190 shares of the company’s common stock on January 9, 2026 at a weighted average price of $1.0708 per share. After this transaction, he beneficially owned 329,708 shares.
According to the filing, the shares were sold only in an amount required to cover tax withholding obligations arising from the vesting of 8,326 shares underlying previously granted RSUs. The sales were automatically executed under an irrevocable sell-to-cover election and were not made at his discretion.
Fate Therapeutics has a Form 144 notice indicating a shareholder plans to sell 10,589 shares of common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of 11,275.17. These shares were acquired on 01/08/2026 via restricted stock vesting as compensation from the issuer. Shares of common stock outstanding were 115,352,289 at the time referenced, which serves as a baseline figure.
A shareholder has filed a notice of intent to sell 5,190 shares of common stock through Fidelity Brokerage Services LLC on or about 01/09/2026, with trading on the NASDAQ exchange. The shares have an aggregate market value of $5,557.45 based on the information provided and are part of a total of 115,352,289 shares outstanding. These securities were acquired from the issuer on 01/08/2026 through restricted stock vesting as compensation, with the same date shown for acquisition and payment.
Fate Therapeutics reported Q3 2025 results. Collaboration revenue was $1.7 million, down from $3.1 million a year ago, reflecting lower recognition under its Ono collaboration. Operating expenses fell to $36.5 million from $55.5 million as R&D and G&A were reduced. Net loss narrowed to $32.3 million from $47.7 million, and loss per share improved to $0.27 from $0.40.
Liquidity and cash flows: Cash and cash equivalents were $40.6 million, with short-term investments of $174.8 million and long-term investments of $10.3 million. Total current assets were $221.3 million. Net cash used in operations for the nine months was $82.8 million, partially offset by $83.5 million net inflows from investment activity and $3.8 million from a CIRM award.
Operational updates: The company implemented an August 2025 restructuring, recording $1.1 million in severance and related costs. It recognized $1.7 million in Q3 revenue and $5.3 million year-to-date under the Ono arrangement, with committed funding through June 2026. As of November 6, 2025, 115,352,289 common shares were outstanding.
Fate Therapeutics, Inc. (FATE) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1.
The disclosure was provided under Item 2.02 (Results of Operations and Financial Condition) and is being furnished, not filed, under the Exchange Act. The report was signed by President and Chief Executive Officer Bahram Valamehr.
Fate Therapeutics (FATE) reported an early clinical update for FT819, its off-the-shelf, CD19-targeted CAR T-cell candidate, in moderate-to-severe systemic lupus erythematosus. As of the September 25, 2025 data cut-off, 10 patients received a single FT819 dose in a Phase 1 study and data were highlighted at ACR Convergence 2025.
The trial evaluates FT819 with either less‑intensive conditioning (cyclophosphamide or bendamustine) or no conditioning. In the less‑intensive arm, the company observed rapid, sustained CD19+ B‑cell depletion that correlated with dose, followed by emergence of naïve B cells beyond baseline, consistent with an immune reset and reduction in disease burden. Without conditioning, reductions in CD19+ B cells and expanded B‑cell clones were seen, alongside improvements in disease activity scores.
Fate also initiated independent dose‑expansion cohorts in AAV, IIM, and SSc, and is engaging the FDA under its RMAT designation to align on a registrational study design with a goal to start a pivotal study in 2026.